Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Newsrooms everywhere are grappling with the opportunities and risks of using generative AI tools. The Poynter Institute aims to support journalists in using these tools ethically and responsibly, in ...

Through teaching, publishing, convening, fact-checking and media literacy, Poynter creates a crossroads where communities come together to use journalism to confront society’s complex problems.